Proximagen Limited

Amura Therapeutics Limited

Benevolental Cambridge Limited

Benevolentai Cambridge Limited

Proximagen Group Limited

Lee Patient

Edward Savory

Iain Simpson

David Evans

Max Espensen

Michael Higginbottom

Andrew Graham Cole

Kathryn Oliver

Allison Carley

Alison Stewart

Giles Brown

Giles Albert Brown

Martin Quibell

John Paul Watts

Viet-Anh Anne Horgan

Claudio Dagostin

Michael Ashwood

Olof Haglund

Allison Powell

James Nally

Yikang Wang

A compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof and the use of the same in therapy: wherein Z, Y, R, W, V, and Rare as defined in claim. 

Imidazo[4,5-C]pyridine derived SSAO inhibitors

Compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that are inhibitors of SSAO activity: where V, W, X, Y, Z, R, and Rare as defined herein.

Substituted imidazo[4,5-c]pyridine compounds and compositions thereof

The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R, X, Y and Rare as defined in the claims.

CXCR4 receptor antagonists

The invention relates to an improved process for the synthesis of (3S, 4S)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3H-imidazo[4,5-c]pyridine-5(4H)-carboxylate, and pharmaceutically acceptable salts thereof, such as the methanesulphonic acid salt.

Process for the preparation of (3S,4S)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3H-imidazo[4,5-C]pyridine-5(4H)-carboxylate

A process for the preparation of a compound of formula (Ia) or a pharmaceutically acceptable salt, or N-oxide thereof that includes reacting a compound of formula (IIIa) or (Va) with a compound of formula (IX) to form the compound of formula (Ia) 

Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors

The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, Rand Rare as defined in the claims.

{4-[3-(Dimethylamino)propoxy]phenyl}methyl (4S)-4-(propan-2-yl)-3H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carboxylate, and pharmaceutically or veterinarily acceptable salts thereof. 

Therapeutic compound and use in therapy

The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.

Compounds

Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors

Specific compounds of formula (Ia): and pharmaceutically acceptable salts thereof. Pharmaceutical compositions of the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof. A method for inhibiting tumor growth in a subject that includes administering to the subject an effective amount of a compound selected from the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof. A method for modulating semicarbazide-sensitive amine oxidase activity in a subject that includes administering to the subject an effective amount of a compound selected from the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof.

Substituted imidazo[4,5-c]pyridines as SSAO inhibitors

The compounds of formula (I) are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) activity useful in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumor growth. 

The compound of formula (I) are inhibitors of SSAO activity (Formula (I)) wherein the terms Y, Z, W, Rand Rare defined in the claims. 

Growing community of inventors

Linton, United Kingdom

Lee Patient